Close Menu

NEW YORK (GenomeWeb) – CareFirst Blue Cross Blue Shield said today that it will cover Exosome Diagnostics' ExoDx Prostate IntelliScore (EPI) prostate cancer test based on the results of an evidence development study launched last year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 


As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.